Aadi Bioscience (NASDAQ:AADI) Trading Down 0.6% – Should You Sell?

Aadi Bioscience, Inc. (NASDAQ:AADI) dropped 0.6% on Wednesday . The company traded as low as $1.52 and last traded at $1.54. Approximately 30,847 shares traded hands during trading, a decline of 88% from the average daily volume of 250,159 shares. The stock had previously closed at $1.55.

Aadi Bioscience Trading Down 0.6 %

The company has a fifty day simple moving average of $2.01 and a 200-day simple moving average of $2.36. The company has a market capitalization of $38.03 million, a PE ratio of -0.68 and a beta of 0.68.

Aadi Bioscience (NASDAQ:AADI) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.37). Aadi Bioscience had a negative return on equity of 71.87% and a negative net margin of 246.06%. The firm had revenue of $7.24 million for the quarter, compared to analyst estimates of $7.45 million. On average, equities analysts predict that Aadi Bioscience, Inc. will post -2.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Aadi Bioscience

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Peapod Lane Capital LLC purchased a new position in shares of Aadi Bioscience during the 4th quarter worth $1,397,000. BML Capital Management LLC boosted its stake in Aadi Bioscience by 5.0% during the fourth quarter. BML Capital Management LLC now owns 2,100,000 shares of the company’s stock worth $6,626,000 after buying an additional 100,000 shares during the period. Geode Capital Management LLC increased its position in shares of Aadi Bioscience by 4.1% during the fourth quarter. Geode Capital Management LLC now owns 217,294 shares of the company’s stock valued at $686,000 after acquiring an additional 8,546 shares during the last quarter. QVT Financial LP purchased a new stake in shares of Aadi Bioscience in the 4th quarter valued at approximately $7,300,000. Finally, Northern Trust Corp lifted its holdings in shares of Aadi Bioscience by 33.1% in the 4th quarter. Northern Trust Corp now owns 91,151 shares of the company’s stock worth $288,000 after acquiring an additional 22,677 shares during the last quarter. Institutional investors and hedge funds own 52.08% of the company’s stock.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.